跳转至内容
Merck
CN

SML3846

Motixafortide trifluoroacetate

≥95% (HPLC)

别名:

TF 14016 trifluoroacetate, B 4F-benzoyl-TN14003 trifluoroacetate, BKT 140 trifluoroacetate, BKT140 trifluoroacetate, N2-(4-Fluorobenzoyl)-L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl- L-argininamide cyclic (4→13)-disulfide trifluoroacetate, TF14016 trifluoroacetate

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C97H144FN33O19S2 · xC2HF3O2
分子量:
2159.52 (free base basis)
UNSPSC Code:
51111800
NACRES:
NA.21

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

O=C(NCCCC1NC(C(CCCNC(N)=N)NC(C(CC2=CC=C(C=C2)O)NC(C3N(CCC3)C(C(CCCCN)NC(C(CCCCN)NC(C(CCCNC(N)=O)NC(C(CC4=CC=C(C=C4)O)NC(C(CSSCC(C(NC(CCCNC(N)=N)C(N)=O)=O)NC1=O)NC(C(CC5=CC6=C(C=CC=C6)C=C5)NC(C(CCCNC(N)=N)NC(C(CCCNC(N)=N)NC(C7=CC=C(C=C7)F)=O)=O)=O)=O)=O)=O

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

Quality Level

100

Biochem/physiol Actions

Motixafortide (BKT140, BL-8040) is an orally available, highly selective inverse agonist of CXCR4 (CXC Chemokine Receptor 4). Motixafortide is a potent stem cell mobiliser and anticancer agent. BKT140 potently inhibits CXCL12 induced migration/invasion of small-cell lung cancer cells.
Orally available, highly selective inverse agonist of CXCR4

Disclaimer

Hygroscopic

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
Leukemia, 31(11), 2336-2346 (2017)
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003
Stem Cells, 25(9), 2158-2166 (2007)
Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140
Clinical Cancer Research, 19(13), 3495-3507 (2013)

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持